177Lu-DOTA-EB-FAPI

N/A

Report date: 2025/09/24 14:01:29

Base Information

Drug Name177Lu-DOTA-EB-FAPI
Drug Alias NameN/A
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionRadionuclide imaging enhancersFibroblast activation protein alpha inhibitors
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsOncocytic cell carcinoma of the thyroidSolid tumoursThyroid Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesThe First Affiliated Hospital Of Xiamen University
China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital Of Xiamen University
Inactive CompaniesN/A
Active IndicationsOncocytic cell carcinoma of the thyroidSolid tumoursThyroid Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A